Longitudinal dynamics of antibody responses in recovered COVID-19 patients

摘要

Antibody responses against SARS-CoV-2 spike protein in COVID-19 recovered individuals. IgG (a), IgM (c), and NT50 titers (e) against SARS-CoV-2 S-RBD or S protein of the recovered patients from 5–7 to 34–42 weeks (n = 17). Comparison of the IgG (b), IgM (d), and NT50 titers (f) between mild and severe patients from 5–7 to 34–42 weeks (n = 24). g Correlation analysis of NT50 titers and IgG titers of the recovered patients during 5–42, 5–7, 8–10, 11–13, 14–16, and 34–42 weeks. h Comparison of the PRNT50 titers between mild and severe patients during 5–7 (n = 14) and 14–16 (n = 14) weeks. i Correlation analysis of NT50 titers and PRNT50 titers of the recovered patients during 5–16 weeks (n = 28). Anti-RBD IgG neutralization potency index (NT50/IgG) was calculated (j) and compared between mild and severe patients (k) from 5–7 to 34–42 weeks (n = 24). l Comparison of the anti-RBD IgG neutralization potency index (NT50/IgG) between the patients who treated with corticosteroids or not from 5–7 to 34–42 weeks (n = 24). m The longitudinal dynamics of the anti-RBD IgG neutralization potency index (NT50/IgG) in mild patients who treated with corticosteroids or not (n = 7). n Seroprevalence of the IgG, IgM, NT50, and PRNT50 titers in patients from 5–7 to 34–42 weeks after symptom onset (5–7, n = 14; 8–10, n = 12; 11–13, n = 17; 14–16, n = 10; 34–42, n = 8). n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001